TY - JOUR
KW - Plasmodium falciparum
KW - malaria
KW - microphysiological systems
KW - organ-on-a-chip
AU - Michael J. Rupar
AU - Hannah M. Hanson
AU - Brianna L. Botlick
AU - Narasimhan Sriram
AU - Stephanie Rogers
AU - Justin Zuniga
AU - Zhanhe Liu
AU - Steven J. Trimmer
AU - Joseph M. Ciurca
AU - Christopher J. Long
AU - Christopher W. McAleer
AU - Stephan Schmidt
AU - Paola Favuzza
AU - Philip Lowe
AU - Nathalie Gobeau
AU - James J. Hickman
AB - In 2023 malaria claimed ≈600000 lives, with 90% of those deaths attributed to the Plasmodium falciparum parasite. This resurgence in mortality emphasizes the necessity of adopting alternative models to accelerate therapeutic development. The Malaria-on-a-Chip model used here incorporated human liver, spleen, and endothelium with P. falciparum-infected blood, and was maintained for 7 days using serum-free medium. This model sustained all stages of the intraerythrocytic life cycle and allowed for organ–organ interaction, providing advantageous preclinical insight into malaria pathophysiology. Chloroquine, lumefantrine, or artesunate were delivered as monotherapies to 3D7 or W2-infected systems. Dose-dependent parasite clearance was observed in both strains for all compounds. Recrudescence occurred in the 3D7-infected model following treatment with chloroquine or lumefantrine, but not artesunate. In W2-infected systems, chloroquine and lumefantrine treatment resulted in parasitemia stabilization by day 7, while artesunate further reduced parasitemia. Population dynamics modeling of pharmacokinetic and pharmacodynamic (PK/PD) outcomes were utilized to predict human in vivo parameters for efficacy and off-target toxicity using in vitro results.
BT - Advanced Science
DO - 10.1002/advs.202505206
IS - n/a
LA - en
N2 - In 2023 malaria claimed ≈600000 lives, with 90% of those deaths attributed to the Plasmodium falciparum parasite. This resurgence in mortality emphasizes the necessity of adopting alternative models to accelerate therapeutic development. The Malaria-on-a-Chip model used here incorporated human liver, spleen, and endothelium with P. falciparum-infected blood, and was maintained for 7 days using serum-free medium. This model sustained all stages of the intraerythrocytic life cycle and allowed for organ–organ interaction, providing advantageous preclinical insight into malaria pathophysiology. Chloroquine, lumefantrine, or artesunate were delivered as monotherapies to 3D7 or W2-infected systems. Dose-dependent parasite clearance was observed in both strains for all compounds. Recrudescence occurred in the 3D7-infected model following treatment with chloroquine or lumefantrine, but not artesunate. In W2-infected systems, chloroquine and lumefantrine treatment resulted in parasitemia stabilization by day 7, while artesunate further reduced parasitemia. Population dynamics modeling of pharmacokinetic and pharmacodynamic (PK/PD) outcomes were utilized to predict human in vivo parameters for efficacy and off-target toxicity using in vitro results.
EP - e05206
T2 - Advanced Science
TI - Translation of a Human-Based Malaria-on-a-Chip Phenotypic Disease Model for In Vivo Applications
UR - https://onlinelibrary.wiley.com/doi/abs/10.1002/advs.202505206
VL - n/a
Y2 - 2025-10-02
SN - 2198-3844
ER -